Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

North America Anti-Obesity Drugs Market Outlook

The North America anti-obesity drugs market size is expected to grow at a CAGR of 9.30% during the forecast period of 2024-2032, driven by the rising prevalence of obesity and the growing demand for effective anti-obesity drugs with fewer side effects in the region. 

Key Takeaways

  • In the United States, 41.9% of adults are estimated to be obese. The rising prevalence of obesity directly impacts the demand for effective and affordable anti-obesity drugs.
  • In November 2023, the FDA approved Zepbound developed by Eli Lilly and Company for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication. The market is witnessing a surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA), which is expected to boost the North America anti-obesity drugs market share in the forecast period.
  • In August 2023, Novo Nordisk A/S planned to acquire a Canada-based biotechnology company Inversago Pharma in a deal worth over USD 1 billion to expand its obesity and diabetes portfolio. Such strategic partnerships are expected to lead to accelerated development and commercial availability of innovative anti-obesity drugs.

North America Anti-Obesity Drugs Market Analysis

Anti-obesity drugs are expected to aid in weight management with minimal side effects by inducing fat absorption, appetite suppression, and metabolic enhancement, among others. In North America, there is a rising acceptance of obesity as a chronic disease requiring medical intervention rather than just lifestyle changes. This shift in perception coupled with heightened patient awareness and the presence of advanced healthcare infrastructure in the region is expected to contribute to the North America anti-obesity drugs market growth.

Recent data suggests that obesity rates in North America are sharply increasing. In the United States, 41.9% of adults are estimated to be obese, out of which, Black and Latino populations have the highest rates of obesity at 49.9% and 45.6%, respectively. The rising prevalence of obesity impacts the demand for effective and affordable anti-obesity therapeutics significantly. Furthermore, the increased focus on research in obesity management to combat the growing cases in the region is anticipated to boost market size in coming years.

One of the significant North America anti-obesity drugs market trends is the surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA). In November 2023, the FDA approved Eli Lilly and Company manufactured Zepbound (containing the active ingredient tirzepatide). It is designed for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication. Zepbound is known to activate certain hormone receptors in the intestine that reduce food intake and suppress appetite. Its efficacy was evaluated in two randomized controlled trials which showed that Zepbound can result in a statistically significant reduction in body weight. The increased availability of such effective anti-obesity drugs is likely to elevate market value.

The market is witnessing increased merger and acquisition initiatives from the key market players. Such strategic partnerships are expected to lead to accelerated development and commercial availability of innovative therapeutics, thereby fuelling North America anti-obesity drugs market demand. In September 2023, Novo Nordisk A/S acquired a Canada-based biotechnology company, called Inversago Pharma in a deal worth over USD 1 billion. The partnership was intended to expand its obesity and diabetes portfolio. The company also aims to assess the potential of Inversago’s lead candidate, INV-202, which is known to block the CB1 receptor involved in the regulation of appetite and metabolism, in obesity and associated complications. Such substantial investments in the anti-obesity drug pipelines are expected to improve access to obesity treatments, which will positively impact the market share.

North America Anti-Obesity Drugs Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup Categories
Drugs Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, Tirzepatide
Drug Class Amphetamine, GLP-1 receptor agonist, Lipase Inhibitor
Mechanism of Action Centrally Acting Drugs, Peripherally Acting Drugs
Route of Administration Oral, Subcutaneous
Prescription Type Prescription Drugs, Over the Counter Drugs
Distribution Channel Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies
Countries United States of America, Canada

North America Anti-Obesity Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Pfizer, Inc.
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline PLC
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals, Inc.
  • Gelesis Holdings Inc. (PureTech Health)
  • Currax Pharmaceutical LLC (Currax Holdings USA LLC)
  • Vivus LLC
  • Cheplapharm Arzneimittel GmbH (Braun Beteiligungs GmbH)
  • KVK Tech, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drugs
  • Drug Class
  • Mechanism of Action 
  • Route of Administration
  • Prescription Type
  • Distribution Channel
  • Region
Breakup by Drugs
  • Semaglutide 
  • Phentermine/Topiramate 
  • Naltrexone/Bupropion 
  • Liraglutide 
  • Gelesis 100 
  • Orlistat 
  • Phentermine 
  • Methamphetamine 
  • Tirzepatide  
Breakup by Drug Class
  • Amphetamine
  • GLP-1 receptor agonist
  • Lipase Inhibitor  
Breakup by Mechanism of Action
  • Centrally Acting Drugs
  • Peripherally Acting Drugs 
Breakup by Route of Administration
  • Oral
  • Subcutaneous 
Breakup by Prescription Type
  • Prescription Drugs 
  • Over The Counter Drugs  
Breakup by Distribution Channel
  • Hospital Pharmacies 
  • Drug Store & Retail Pharmacies 
  • Online Pharmac
Breakup by Region
  • United States of America
  • Canada
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer, Inc.
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline PLC
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals, Inc.
  • Gelesis Holdings Inc. (PureTech Health)
  • Currax Pharmaceutical LLC (Currax Holdings USA LLC)
  • Vivus LLC
  • Cheplapharm Arzneimittel GmbH (Braun Beteiligungs GmbH)
  • KVK Tech, Inc.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market is anticipated to grow at a CAGR of 9.30% during the forecast period of 2024-2032, driven by the rising prevalence of obesity in the region.

The increasing awareness about the health risks associated with obesity and the rising disposable incomes in the region are fuelling the demand for the market.

One of the significant trends in the market is the surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA). In November 2023, the FDA approved Zepbound developed by Eli Lilly and Company for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication.

Based on the drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide.

Drug classes available in the market include amphetamine, GLP-1 receptor agonists, and lipase inhibitors. 

By mechanism of action, the market is divided into centrally acting drugs and peripherally acting drugs.

The market breakup by route of administration includes oral and subcutaneous.

Based on the prescription type, the market includes prescription drugs and over-the-counter drugs.

Distribution channels of the market include hospital pharmacies, drug store & retail pharmacies, and online pharmacies. 

The market segmentation by countries includes the United States of America and Canada. 

The key players in the market are Pfizer, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis Holdings Inc. (PureTech Health), Currax Pharmaceutical LLC (Currax Holdings USA LLC), Vivus LLC, Cheplapharm Arzneimittel GmbH (Braun Beteiligungs GmbH), and KVK Tech, Inc.

Purchase Full Report

Datasheet

 

USD 2,639

USD 2,399

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 4,399

USD 3,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 5,829

USD 5,299

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 6,929

USD 6,299

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124